Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
348 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04128072 | Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma(MOGAT) | recruiting | Phase 2 | 43 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Apr 5, 2024 | clinicaltrials |
| NCT00036868 | Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTC |
| 9 |
| Mar 8, 2024 |
| clinicaltrials |
| NCT00424164 | Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer(LAPATAM) | completed | Phase 1 | 20 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03770468 | Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma | completed | — | 599 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Mar 8, 2024 | clinicaltrials |
| NCT05209529 | Chemo-free BRCA-targeted Neoadjuvant Strategy | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 23, 2024 | clinicaltrials |
| NCT03357224 | PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)(PARCT) | terminated | Phase 2 | 26 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT04780464 | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma(Tolerance) | terminated | Phase 3 | 14 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT04995575 | Dissecting the Pathways of Therapy Resistance in Early Breast Cancer(MINDACTRelapse) | terminated | — | 31 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 22, 2024 | clinicaltrials |
| NCT02781935 | Diffusion-Weighted MRI for Liver Metastasis(DREAM) | completed | — | 233 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Jan 5, 2024 | clinicaltrials |
| NCT03443856 | Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence(VESTIGE) | unknown | Phase 2 | 197 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jan 5, 2024 | clinicaltrials |
| NCT01288378 | Empirical Versus Preemptive Antifungal Therapy | completed | Phase 3 | 556 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Dec 11, 2023 | clinicaltrials |
| NCT01402271 | Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | completed | Phase 1 / Phase 2 | 88 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT01524926 | CREATE: Cross-tumoral Phase 2 With Crizotinib(CREATE) | completed | Phase 2 | 582 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Dec 11, 2023 | clinicaltrials |
| NCT02580994 | Pembrolizumab in Untreated Extensive SCLC(REACTION) | completed | Phase 2 | 125 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Dec 11, 2023 | clinicaltrials |
| NCT01942603 | Minimal SN Tumor Burden(Minitub) | active not recruiting | — | 296 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Nov 28, 2023 | clinicaltrials |
| NCT04218825 | REACH: Study to Determine the Aetiology of Chlormethine Gel Induced-skin Drug Reaction in Early Stage Mycosis Fungoides Cutaneous T Cell Lymphoma (MF-CTCL)(REACH) | terminated | Phase 2 | 2 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Nov 9, 2023 | clinicaltrials |
| NCT03088059 | Biomarker-based Study in R/M SCCHN(UPSTREAM) | unknown | Phase 2 | 340 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 3, 2023 | clinicaltrials |
| NCT03260712 | Pembrolizumab in Biliary Tract Cancer | completed | Phase 2 | 50 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Nov 3, 2023 | clinicaltrials |
| NCT04790253 | PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)(PRIMALung) | recruiting | N/A | 600 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Nov 3, 2023 | clinicaltrials |
| NCT00626990 | Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)(CATNON) | active not recruiting | Phase 3 | 751 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | Sep 11, 2023 | clinicaltrials |
| NCT04933942 | Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma(RIGOLETTO) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | May 24, 2023 | clinicaltrials |
| NCT01344018 | Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma(STRASS) | completed | N/A | 266 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Apr 24, 2023 | clinicaltrials |
| NCT02659384 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | completed | Phase 2 | 122 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Mar 14, 2023 | clinicaltrials |
| NCT03437200 | Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer(CRUCIAL) | terminated | Phase 2 | 8 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Feb 21, 2023 | clinicaltrials |
| NCT02172872 | "InDACtion" vs "3+7" Induction in AML | unknown | Phase 3 | 606 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Feb 15, 2023 | clinicaltrials |
| NCT00433589 | Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes(MINDACT) | completed | Phase 3 | 6,600 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Nov 17, 2022 | clinicaltrials |
| NCT01597414 | Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 | completed | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Nov 17, 2022 | clinicaltrials |
| NCT02436733 | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM | unknown | Phase 2 | 64 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Nov 7, 2022 | clinicaltrials |
| NCT01723969 | Screening Platform for Clinical Trials in Advanced Colorectal Cancer(SPECTAcolor) | completed | — | 668 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Jul 7, 2022 | clinicaltrials |
| NCT04796454 | Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer(PAMICC) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jun 1, 2022 | clinicaltrials |
| NCT02218801 | A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program(CLIMB) | completed | — | 219 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 12 | May 31, 2022 | clinicaltrials |
| NCT03101475 | Synergism of Immunomodulation and Tumor Ablation(ILOC) | completed | Phase 2 | 22 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | May 31, 2022 | clinicaltrials |
| NCT01880359 | AF CRT +/- Nimorazole in HNSCC | unknown | Phase 3 | 640 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | May 10, 2022 | clinicaltrials |
| NCT03763422 | Trial in Low Grade Glioma Patients: Wait or Treat(IWOT) | terminated | Phase 3 | 19 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Feb 1, 2022 | clinicaltrials |
| NCT03319316 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)(SOLUTION) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 10, 2022 | clinicaltrials |
| NCT02808247 | Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma(ANITA) | terminated | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 20, 2021 | clinicaltrials |
| NCT01913652 | Ph II Cabazitaxel DD Liposarcoma | completed | Phase 2 | 42 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 14, 2021 | clinicaltrials |
| NCT03563040 | Study of Photopheresis in the Treatment of Erythrodermic MF and SS(PROMPT) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02216578 | Ph II CABOGIST in GIST | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 15, 2021 | clinicaltrials |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC(ADHERE) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 10, 2021 | clinicaltrials |
| NCT01838577 | Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study(GEM) | unknown | — | 2,000 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | completed | Phase 3 | 475 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 18 | Feb 15, 2021 | clinicaltrials |
| NCT01290939 | Bevacizumab and Lomustine for Recurrent GBM | completed | Phase 3 | 592 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT01652261 | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)(H11) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT00433433 | Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma(H10) | unknown | Phase 3 | 1,952 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00626730 | Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma | unknown | Phase 2 | 78 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03620149 | Reduced Dose-density of Denosumab for Unresectable GCTB(REDUCE) | terminated | Phase 2 | 2 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 6, 2021 | clinicaltrials |
| NCT02929394 | Trabectedin Maintenance Post 1st-line in STS | terminated | Phase 3 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 2, 2020 | clinicaltrials |
| NCT03488810 | Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer(ARN-509) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Aug 17, 2020 | clinicaltrials |
| NCT01788982 | Nintedanib(BIBF1120) in Thyroid Cancer | completed | Phase 2 | 100 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 31, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials